Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SP, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K, Kim J. Pethe K, et al. Among authors: nam k, nam j. Nat Med. 2013 Sep;19(9):1157-60. doi: 10.1038/nm.3262. Epub 2013 Aug 4. Nat Med. 2013. PMID: 23913123 Free article.
Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.
Kang S, Kim RY, Seo MJ, Lee S, Kim YM, Seo M, Seo JJ, Ko Y, Choi I, Jang J, Nam J, Park S, Kang H, Kim HJ, Kim J, Ahn S, Pethe K, Nam K, No Z, Kim J. Kang S, et al. Among authors: nam k, nam j. J Med Chem. 2014 Jun 26;57(12):5293-305. doi: 10.1021/jm5003606. Epub 2014 Jun 17. J Med Chem. 2014. PMID: 24870926
Telacebec (Q203), a New Antituberculosis Agent.
de Jager VR, Dawson R, van Niekerk C, Hutchings J, Kim J, Vanker N, van der Merwe L, Choi J, Nam K, Diacon AH. de Jager VR, et al. Among authors: nam k. N Engl J Med. 2020 Mar 26;382(13):1280-1281. doi: 10.1056/NEJMc1913327. N Engl J Med. 2020. PMID: 32212527 Clinical Trial. No abstract available.
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial.
Kim J, Choi J, Kang H, Ahn J, Hutchings J, Niekerk CV, Kim J, Jeon Y, Nam K, Kim TH, Shin BS, Shin S. Kim J, et al. Among authors: nam k. Antimicrob Agents Chemother. 2023 Jan 24;67(1):e0112322. doi: 10.1128/aac.01123-22. Epub 2022 Dec 12. Antimicrob Agents Chemother. 2023. PMID: 36507677 Free PMC article. Clinical Trial.
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity.
Yu D, Wagner S, Schütz M, Jeon Y, Seo M, Kim J, Brückner N, Kicuntod J, Tillmanns J, Wangen C, Hahn F, Kaufer BB, Neipel F, Eickhoff J, Klebl B, Nam K, Marschall M. Yu D, et al. Among authors: nam k. Pharmaceutics. 2024 Jan 23;16(2):158. doi: 10.3390/pharmaceutics16020158. Pharmaceutics. 2024. PMID: 38399219 Free PMC article.
3,251 results